Your investments deserve an analyst, not a dashboard.

Normalised Returns

Healthcare Service Provider · closest in market value

0% = 17 Dec 2025 close

NEPHROPLUS+47.8%Nifty Pharma+19.4%

adjusted closes, rebased to 0% · dashed line is the index · hover a peer to highlight it, click to keep itCharts by TradingView

Full Comparison

NSE filings · last close

Company	Price	Mkt Cap	P/E	P/B	ROE	Margin	Rev YoY	PAT YoY	D/E	1Y Rtn
VIJAYA	₹1,514	₹15,574 Cr	83.1×	16.27×	19.7%	21.2%	+22.8%	+37.6%	0.00×	+48.6%
METROPOLIS	₹582.6	₹12,079 Cr	59.6×	7.98×	13.4%	11.6%	+16.6%	+25.7%	0.01×	+15.3%
THYROCARE	₹566.85	₹9,023 Cr	51.3×	15.41×	28.8%	19.6%	+24.3%	+34.1%	0.00×	+44.6%
NEPHROPLUS ●	₹696.65	₹6,990 Cr	–	6.26×	6.9%	7.7%	–	–	0.07×	–
SURAKSHA	₹343.3	₹1,788 Cr	49.7×	7.30×	13.8%	10.1%	+20.7%	+40.0%	0.01×	+15.0%
KRSNAA	₹548.45	₹1,779 Cr	18.3×	1.81×	10.9%	13.1%	+22.1%	−19.3%	0.55×	−28.8%

Healthcare Service Provider: the companies closest in market value, of the 9 in that basic industry whose filings we hold, from each company's NSE filings and the last close. Quarterly figures are for Q1 FY27; ROE, margin for FY26; P/B and D/E on the latest balance sheet. Green and red mark the two ends of a column; valuation and leverage columns are left plain. Hover a heading for its definition.

Against Healthcare Service Provider9 companies

P/E—

18.6×median 55.5× · 6 companies86.1×

P/B6.69×

1.45×median 7.51× · 6 of 9, highest first16.9×

ROE—

-4.1%median 14.7% · 7 companies30.0%

Net margin—

-1.8%median 12.0% · 7 companies21.9%

Revenue growth—

10.2%median 21.1% · 7 companies28.8%

Profit growth—

5.4%median 22.9% · 6 companies39.7%

Debt / equity0.07×

0.00×median 0.01× · 3 of 9, highest first0.55×

Dividend yield—

0.1%median 0.6% · 6 companies2.5%

1-year price change—

-32.5%median 15.0% · 7 companies45.5%

Everyone in Healthcare Service Provider whose filings we hold: 9 companies, its basic industry within Healthcare. Figures as the screener works them out (the last four quarters' profit, the latest balance sheet, the last close), so ROE can differ a little from the Financials tab's latest-year figure. A place in the line is a fact about a number, not a view on the company.

NEPHROPLUS Rankings

Among 6 companies compared

Profitability

ROE 6.9%Lowest of 6

Net margin 7.7%Lowest of 6

Leverage

Debt / equity 0.07×5th lowest of 6

Valuation

P/Book 6.26×2nd lowest of 6

Position 1 is the lowest NPA, multiple or leverage, and the highest return, growth or profitability figure. These are positions among the companies listed here, not a view on the stock.